Strategic Advocates’s ResMed RMD Stock Holding History

Strategic Advocates’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9	Closed	-$2.19K	–	530
2025 Q4	$2.19K	Hold	9	–	–	﹤0.01%	490
2025 Q3	$2.46K	Buy	+9	New	+$2.46K	﹤0.01%	462

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Strategic Advocates's RMD Position: Q1 2026 in Review

Strategic Advocates sold out of ResMed (RMD) in Q1 2026, closing a stake of 9 shares — an estimated $2.19K sold.

Strategic Advocates first reported a position in RMD in Q3 2025 and held it in 2 quarters. The position peaked at $2.46K in Q3 2025. 940 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Strategic Advocates reported no remaining ResMed position as of Q1 2026 after selling out during the quarter.
Strategic Advocates sold 9 ResMed shares in Q1 2026, an estimated $2.19K.
Strategic Advocates first reported a position in ResMed in Q3 2025 and held it in 2 quarters.
Strategic Advocates's ResMed position peaked at $2.46K in Q3 2025.
940 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.